Practice
BPCIA Litigation
We counsel innovator and biosimilar companies through every phase of the complex patent disputes that arise under the Biologics Price Competition and Innovation Act. Our team has navigated the BPCIA’s unique procedural requirements, including the patent dance, preliminary injunction practice, and multi-patent infringement campaigns, on behalf of clients in some of the most significant biosimilar disputes in recent years, involving blockbuster biologics across oncology, immunology, and other critical therapeutic areas. We pair that litigation depth with the scientific fluency needed to engage credibly with issues of protein engineering, antibody structure, and biologic manufacturing processes.
